Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items (2019 - 2025)

BridgeBio Pharma's Non-cash Items history spans 7 years, with the latest figure at $205.3 million for Q2 2025.

  • For Q2 2025, Non-cash Items rose 210.5% year-over-year to $205.3 million; the TTM value through Jun 2025 reached $205.3 million, up 210.5%, while the annual FY2024 figure was $13.7 million, 13.46% up from the prior year.
  • Non-cash Items for Q2 2025 was $205.3 million at BridgeBio Pharma, up from $130.9 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $205.3 million in Q2 2025 and bottomed at $494850.0 in Q3 2021.
  • The 5-year median for Non-cash Items is $10.6 million (2023), against an average of $32.4 million.
  • The largest annual shift saw Non-cash Items crashed 99.02% in 2021 before it skyrocketed 5229.73% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $8.0 million in 2021, then crashed by 82.06% to $1.4 million in 2022, then soared by 748.28% to $12.1 million in 2023, then rose by 13.46% to $13.7 million in 2024, then surged by 1394.65% to $205.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Non-cash Items are $205.3 million (Q2 2025), $130.9 million (Q1 2025), and $13.7 million (Q4 2024).